Home Cart Sign in  
Chemical Structure| 1330782-76-7 Chemical Structure| 1330782-76-7

Structure of Simurosertib
CAS No.: 1330782-76-7

Chemical Structure| 1330782-76-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TAK-931 is an oral CDC7-selective inhibitor as a candidate clinical anticancer drug. It induced S phase delay and replication stress.

Synonyms: TAK-931

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Simurosertib

CAS No. :1330782-76-7
Formula : C17H19N5OS
M.W : 341.43
SMILES Code : O=C1C2=C(NC([C@@]3(CC4CCN3CC4)[H])=N1)C=C(C5=CNN=C5C)S2
Synonyms :
TAK-931
MDL No. :MFCD30802281

Safety of Simurosertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Simurosertib

Hedgehog

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02699749 Nonhematologic Neoplasms, Adva... More >>nced Less << PHASE1 COMPLETED 2019-12-21 Kashiwa, Chiba, Japan|Chuo-ku,... More >> Tokyo, Japan Less <<
NCT03261947 Metastatic Pancreatic Cancer|C... More >>olorectal Cancer|Esophageal Neoplasms|Carcinoma, Non-small-cell Lung Less << PHASE2 COMPLETED 2020-08-24 Sarah Cannon Research Institut... More >>e Oncology Research Consortium, Denver, Colorado, 80218, United States|Sarah Cannon Research Institute, Sarasota, Florida, 34232, United States|Allina Health Virginia Piper Cancer Institute, Minneapolis, Minnesota, 55404, United States|Siteman Cancer Center, Saint Louis, Missouri, 63110, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89119, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States|SCRI - Tennessee Oncology - Nashville - Southern Hills Clinic, Nashville, Tennessee, 37203, United States|Virginia Mason Medical Center, Seattle, Washington, 98101-2756, United States|National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, 104-0045, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.93mL

0.59mL

0.29mL

14.64mL

2.93mL

1.46mL

29.29mL

5.86mL

2.93mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories